UGT1A1 and Hyperbilirubinemia: Pazopanib impedes the metabolism of bilirubin through direct inhibition of UGT1A1, and when prescribed to those harboring UGT1A1 genetic variants, the incidence of hyperbilirubinemia is proposed to be higher.